CD31 peptides for the treatment of thrombotic or autoimmune disorders
US10253085B2 · kind B2 · utility
1Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2015 |
| Grant date | Apr 9, 2019 |
| Priority date | — |
| Expiry date | Sep 11, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.